Lin M S, Huang C S, Leen D Y
Department of Medicine, Cathay General Hospital, Taipei, Taiwan, ROC.
Int J Clin Pharmacol Ther Toxicol. 1988 Dec;26(12):585-7.
To compare the red blood cell (RBC) deformability in hypertensive patients and healthy volunteers and to evaluate the effects of calcium antagonists on RBC deformability in hypertension, forty mild-to-moderate hypertensive patients and forty healthy volunteers, matched for age, sex and smoking habits, were studied. Each patient was randomized to receive one of the four following two-week treatment regimens: nifedipine 10 mg, verapamil 80 mg and diltiazem 60 mg three times a day and no drug. RBC deformability, measured with a gravity driven filtration technique, and mean arterial pressure were determined before and after the treatment. No difference in RBC deformability was observed between hypertensive patients and healthy volunteers. In contrast to the significant reduction in mean arterial pressure, RBC deformability was not altered by any of the three calcium antagonists. We conclude that a two-week treatment with calcium antagonist, at the effective vasodepressor dose, has no effect on RBC deformability in mild-to-moderate hypertensive patients.
为比较高血压患者与健康志愿者的红细胞（RBC）变形性，并评估钙拮抗剂对高血压患者RBC变形性的影响，我们对40例轻度至中度高血压患者和40例年龄、性别及吸烟习惯相匹配的健康志愿者进行了研究。每位患者被随机分配接受以下四种为期两周治疗方案中的一种：硝苯地平10毫克、维拉帕米80毫克和地尔硫䓬60毫克，每日三次，以及不服用药物。采用重力驱动过滤技术测量治疗前后的RBC变形性及平均动脉压。高血压患者与健康志愿者之间未观察到RBC变形性的差异。与平均动脉压显著降低相反，三种钙拮抗剂中的任何一种均未改变RBC变形性。我们得出结论，在有效降压剂量下，为期两周的钙拮抗剂治疗对轻度至中度高血压患者的RBC变形性无影响。
